Literature DB >> 22820293

Targeting PES1 for restoring the ERα/ERβ ratio in breast cancer.

Christoforos Thomas, Jan-Åke Gustafsson.   

Abstract

Alteration of the ERα/ERβ balance is a critical step in breast cancer development and progression, and selective restoration of the activity of estrogen receptors has been proposed as one of the major therapeutic approaches for breast cancer. In this issue of JCI, Cheng et al. show that, by differentially modulating the stability of ERα and ERβ, PES1 increases the ERα/ERβ ratio and triggers breast tumor growth. These findings highlight PES1 as a potential target for the treatment of breast cancer.

Entities:  

Year:  2012        PMID: 22820293      PMCID: PMC3533503          DOI: 10.1172/JCI65133

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  Dissociated overexpression of cathepsin D and estrogen receptor alpha in preinvasive mammary tumors.

Authors:  P Roger; J P Daures; T Maudelonde; C Pignodel; M Gleizes; J Chapelle; C Marty-Double; P Baldet; P Mares; F Laffargue; H Rochefort
Journal:  Hum Pathol       Date:  2000-05       Impact factor: 3.466

2.  Cloning of a novel receptor expressed in rat prostate and ovary.

Authors:  G G Kuiper; E Enmark; M Pelto-Huikko; S Nilsson; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 3.  Estrogen receptors: how do they signal and what are their targets.

Authors:  Nina Heldring; Ashley Pike; Sandra Andersson; Jason Matthews; Guojun Cheng; Johan Hartman; Michel Tujague; Anders Ström; Eckardt Treuter; Margaret Warner; Jan-Ake Gustafsson
Journal:  Physiol Rev       Date:  2007-07       Impact factor: 37.312

4.  Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.

Authors:  Naoko Honma; Rie Horii; Takuji Iwase; Shigehira Saji; Mamoun Younes; Kaiyo Takubo; Masaaki Matsuura; Yoshinori Ito; Futoshi Akiyama; Goi Sakamoto
Journal:  J Clin Oncol       Date:  2008-08-01       Impact factor: 44.544

5.  Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia.

Authors:  Abeer M Shaaban; Penny A O'Neill; Michael P A Davies; Ross Sibson; Christopher R West; Paul H Smith; Christopher S Foster
Journal:  Am J Surg Pathol       Date:  2003-12       Impact factor: 6.394

6.  Role of pescadillo in the transformation and immortalization of mammalian cells.

Authors:  Arianna Maiorana; Xiao Tu; Guanjun Cheng; Renato Baserga
Journal:  Oncogene       Date:  2004-09-16       Impact factor: 9.867

7.  Cloning of the human estrogen receptor cDNA.

Authors:  P Walter; S Green; G Greene; A Krust; J M Bornert; J M Jeltsch; A Staub; E Jensen; G Scrace; M Waterfield
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

8.  Role of pescadillo and upstream binding factor in the proliferation and differentiation of murine myeloid cells.

Authors:  Marco Prisco; Arianna Maiorana; Clara Guerzoni; George Calin; Bruno Calabretta; Renate Voit; Ingrid Grummt; Renato Baserga
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

9.  Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen.

Authors:  Antoni Hurtado; Kelly A Holmes; Timothy R Geistlinger; Iain R Hutcheson; Robert I Nicholson; Myles Brown; Jie Jiang; William J Howat; Simak Ali; Jason S Carroll
Journal:  Nature       Date:  2008-11-12       Impact factor: 49.962

10.  ERbeta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clinicopathological and molecular correlates.

Authors:  Newton A C S Wong; Roger D G Malcomson; Duncan I Jodrell; Nigel P Groome; David J Harrison; Philippa T K Saunders
Journal:  J Pathol       Date:  2005-09       Impact factor: 7.996

View more
  8 in total

1.  Estrogen receptor β sustains epithelial differentiation by regulating prolyl hydroxylase 2 transcription.

Authors:  Paul Mak; Cheng Chang; Bryan Pursell; Arthur M Mercurio
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-04       Impact factor: 11.205

2.  Chaihu-Shugan-San administration ameliorates perimenopausal anxiety and depression in rats.

Authors:  Shujiao Chen; Tetsuya Asakawa; Shanshan Ding; Linghong Liao; Lingyuan Zhang; Jianying Shen; Jie Yu; Kenji Sugiyama; Hiroki Namba; Candong Li
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

3.  Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.

Authors:  Ameet K Mishra; Annelie Abrahamsson; Charlotta Dabrosin
Journal:  Oncotarget       Date:  2016-08-30

4.  microRNA-1271 impedes the development of prostate cancer by downregulating PES1 and upregulating ERβ.

Authors:  Zhenming Jiang; Yuxi Zhang; Xi Chen; Yan Wang; Pingeng Wu; Chengzhang Wu; Dong Chen
Journal:  J Transl Med       Date:  2020-05-24       Impact factor: 5.531

5.  PES1 In Liver Cancer: A Prognostic Biomarker With Tumorigenic Roles.

Authors:  Zhuo Fu; Yan Jiao; Yan-Qing Li; Jian-Ji Ke; Yan-Hui Xu; Bao-Xing Jia; Bin Liu
Journal:  Cancer Manag Res       Date:  2019-11-14       Impact factor: 3.989

Review 6.  The functional role of Pescadillo ribosomal biogenesis factor 1 in cancer.

Authors:  Yong-Zhi Li; Cheng Zhang; Jun-Peng Pei; Wan-Chuan Zhang; Chun-Dong Zhang; Dong-Qiu Dai
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

7.  In Leishmania major, the Homolog of the Oncogene PES1 May Play a Critical Role in Parasite Infectivity.

Authors:  Miriam Algarabel; Celia Fernández-Rubio; Katerina Musilova; José Peña-Guerrero; Andrés Vacas; Esther Larrea; Paul A Nguewa
Journal:  Int J Mol Sci       Date:  2021-11-22       Impact factor: 5.923

8.  PES1 promotes BET inhibitors resistance and cells proliferation through increasing c-Myc expression in pancreatic cancer.

Authors:  Xin Jin; Rui Fang; Ping Fan; Lipeng Zeng; Bin Zhang; Xiaoming Lu; Tao Liu
Journal:  J Exp Clin Cancer Res       Date:  2019-11-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.